Results 51 to 60 of about 2,912 (169)

Activity of Meropenem-Vaborbactam against Carbapenem-Resistant Enterobacteriaceae in a Murine Model of Pyelonephritis [PDF]

Antimicrobial Agents and Chemotherapy, 2018
ABSTRACT The recently approved combination of meropenem and vaborbactam (Vabomere) is highly active against Gram-negative pathogens, especially Klebsiella pneumoniae carbapenemase (KPC)-producing, carbapenem-resistant Enterobacteriaceae .
William J. Weiss, Mark E. Pulse, Phung Nguyen, Kelly Peterson, Jessica Silva, Jerry W. Simecka, David Valtierra, Mojgan Sabet, David C. Griffith   +8 more
openaire   +2 more sources

Pharmacokinetics, safety and population pharmacokinetics/pharmacodynamics analysis of meropenem-vaborbactam in Chinese healthy participants

Frontiers in Pharmacology
BackgroundMeropenem-vaborbactam is a fixed-dose β-lactam/β-lactamase inhibitor combination active against carbapenem-resistant Enterobacterales (CRE), especially Klebsiella pneumoniae carbapenemase (KPC)-producing CRE.
Wanzhen Li, Wanzhen Li, Qiong Wei, Mengting Chen, Mengting Chen, Xiaofen Liu, Xiaofen Liu, Beining Guo, Beining Guo, Yuancheng Chen, Qi Zhang, Wei Guan, Long Shen, Xiaohui Wang, Nanyang Li, Yan Chen, Yan Chen, Xin Li, Xin Li, Yingying Hu, Jing Zhang, Jing Zhang, Jing Zhang, Xiaojie Wu, Xiaojie Wu   +24 more
doaj   +1 more source

Meropenem/Vaborbactam Plus Aztreonam as a Possible Treatment Strategy for Bloodstream Infections Caused by Ceftazidime/Avibactam-Resistant Klebsiella pneumoniae: A Retrospective Case Series and Literature Review

Antibiotics, 2022
Objectives: The aim of this study was to describe our experience of a combination treatment including meropenem/vaborbactam (M/V) plus aztreonam (ATM) for bloodstream infections (BSIs) due to ceftazidime/avibactam-resistant Klebsiella pneumoniae (CAZ/AVI-
Alessandra Belati, Davide Fiore Bavaro, Lucia Diella, Nicolò De Gennaro, Francesco Di Gennaro, Annalisa Saracino   +5 more
doaj   +1 more source

Microbial Etiology and Antimicrobial Resistance in Pneumonia Among Hospitalized Patients in Kazakhstan: A Systematic Review and Single‐Arm Meta‐Analysis of Prevalence Data

Health Science Reports, Volume 9, Issue 4, April 2026.
ABSTRACT Background and Aims Pneumonia is an inflammatory condition of the lower respiratory tract, commonly caused by infection and associated with substantial morbidity and healthcare utilization. The burden of pneumonia on healthcare is exacerbated by limited data on pathogenic causes and associated antimicrobial resistance (AMR). Here, we conducted
Radmir Sarsenov, Maxim Solomadin, Alyona Lavrinenko, Vyacheslav Beloussov, Vitaliy Strochkov, Shynggys Orkara, Nurlan Sandybayev, Sergey Yegorov   +7 more
wiley   +1 more source

Microbiological, Clinical, and PK/PD Features of the New Anti-Gram-Negative Antibiotics: β-Lactam/β-Lactamase Inhibitors in Combination and Cefiderocol—An All-Inclusive Guide for Clinicians

Pharmaceuticals, 2022
Bacterial resistance mechanisms are continuously and rapidly evolving. This is particularly true for Gram-negative bacteria. Over the last decade, the strategy to develop new β-lactam/β-lactamase inhibitors (BLs/BLIs) combinations has paid off and ...
Luigi Principe, Tommaso Lupia, Lilia Andriani, Floriana Campanile, Davide Carcione, Silvia Corcione, Francesco Giuseppe De Rosa, Roberto Luzzati, Giacomo Stroffolini, Marina Steyde, Giuliana Decorti, Stefano Di Bella   +11 more
doaj   +1 more source

NCY‐1 β‐Lactamase Activity Correlates With Antimicrobial Susceptibility of a Clinical Strain of Nocardia cyriacigeorgica

MicrobiologyOpen, Volume 15, Issue 2, April 2026.
This study shows a strong correlation between the β‐lactam susceptibility profile of a clinical isolate of Nocardia cyriacigeorgica and the activity of its β‐lactamase, NCY‐1. Inhibitors of NCY‐1 reduce the minimum inhibitory concentration of amoxicillin.
Julie Couston, Athénaïs Le Marchand, Elisabeth Hodille, Charlotte Genestet, Brune Joannard, Jérôme Feuillard, Yvonne Benito, Oana Dumitrescu, Mickaël Blaise   +8 more
wiley   +1 more source

Reversing Antibiotic Resistance: Strategies From Adjuvants to Innovative Therapeutics

MicrobiologyOpen, Volume 15, Issue 1, February 2026.
Molecular reversal strategies against antibiotic resistance act through three mechanisms: inhibiting resistance gene function, blocking horizontal gene transfer, and modulating host defense. Emerging technologies, such as CRISPR‐Cas gene editing, photodynamic therapy, nanotechnology, and ecological competition, further strengthen these approaches ...
Tianjiao Li, Fei Zeng, Jie Zhang, Yuangong Zhang, Wenjuan Yin   +4 more
wiley   +1 more source

In Vitro Activity of Meropenem-Vaborbactam against Clinical Isolates of KPC-Positive Enterobacteriaceae [PDF]

Antimicrobial Agents and Chemotherapy, 2018
ABSTRACT Vaborbactam (formerly RPX7009) is a novel inhibitor of serine β-lactamases, including Ambler class A carbapenemases, such as KPCs. The current study evaluated the in vitro activity of the combination agent meropenem-vaborbactam against a global collection of 991 isolates of KPC-positive
Hackel, Meredith A., Lomovskaya, Olga, Dudley, Michael N., Karlowsky, James A., Sahm, Daniel F.   +4 more
openaire   +2 more sources

Clinical Epidemiological Analysis of the Genotypic Spectrum and Mortality Risk in Carbapenem‐Resistant Klebsiella pneumoniae (CRKP) Infections

Canadian Journal of Infectious Diseases and Medical Microbiology, Volume 2026, Issue 1, 2026.
Background Carbapenem‐resistant Klebsiella pneumoniae (CRKP) has become a global public health threat, with significantly increased morbidity and mortality among high‐risk inpatients. High‐risk genotypes of CRKP, primarily including K. pneumoniae carbapenemase (KPC), oxacillinase‐48–like (OXA‐48–like), New Delhi metallo‐β‐lactamase (NDM), imipenemase ...
Qiongfang Zhang, Ze Fang, Bo Fang, Hailing Zeng, Jiaojiao Xu, Muhammad Abu Bakr Shabbir   +5 more
wiley   +1 more source

Investigating the Effect of Xylitol on ompK36 Overexpression, Increased Meropenem Susceptibility, and Antibiofilm Activity in a Carbapenem‐Resistant Clinical Strain of Klebsiella pneumoniae

International Journal of Microbiology, Volume 2026, Issue 1, 2026.
Carbapenem‐resistant Klebsiella pneumoniae poses a significant public health threat due to limited therapeutic options. This study investigated the potential of xylitol, a sugar alcohol, to enhance meropenem activity and combat biofilms in a clinical carbapenem‐resistant K. pneumoniae strain (Kp5) and a standard susceptible strain (K. pneumoniae subsp.
Omid Ahlelyorof, John Flanagan, Fereshteh Jabalameli, Reza Beigverdi, Maryam Siroosi, Divakar Sharma   +5 more
wiley   +1 more source